Fitxers

697314.pdf (699.56 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-03-21

Llicència de publicació

cc-by (c) Egli, Adrian et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/177028

IFN Lambda 3/4 locus polymorphisms and IFN Lambda 3 circulating levels are associated with COPD severity and outcomes

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12890-018-0616-6

Resum

Background: Interferon lambdas (IFNLs) have important anti-viral/bacterial and immunomodulatory functions in the respiratory tract. How do IFNLs impact COPD and its exacerbations? Methods: Five hundred twenty eight patients were recruited in a prospective observational multicentre cohort (PROMISE) study. The genetic polymorphisms (rs8099917 and rs12979860) within the IFNL3/4 gene region and circulating levels of IFNL3 in COPD patients were determined and associated with disease activity and outcome during a median follow-up of 24 months. Results: The GG genotype significantly influenced severe exacerbation rate (42 vs. 23%; p = 0.032) and time to severe exacerbation (HR = 2.260; p = 0.012). Compared to the TT or TG genotypes, the GG genotype was associated with severe dyspnoea (modified medical research council score ≥ median 3; 22 vs 42%, p = 0.030). The CC genotype of the rs12979860 SNP was associated with a poorer prognosis (body mass index, airflow obstruction, dyspnea and exercise capacity index ≥ median 4; 46 vs. 36% TC vs. 20.5% TT; p = 0.031). Patients with stable COPD and at exacerbation had significantly lower circulating IFNL3 compared to healthy controls (p < 0.001 and p < 0.001, respectively). Circulating IFNL3 correlated to post-bronchodilator FEV1%predicted and the tissue maturation biomarker Pro-collagen 3. Conclusion: IFNL3/4 polymorphisms and circulating IFNL3 may be associated with disease activity and outcomes in COPD. Trial registration: Clinical Trial registration http://www.isrctn.com/ identifier ISRCTN99586989 on 16 April 2008.

Matèries

Mortalitat, Marcadors bioquímics, Polimorfisme genètic

Matèries (anglès)

Mortality, Biochemical markers, Genetic polymorphisms

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

EGLI, Adrian, et al. IFN Lambda 3/4 locus polymorphisms and IFN Lambda 3 circulating levels are associated with COPD severity and outcomes. BMC Pulmonary Medicine. 2018. Vol. 18, núm. 1, pàgs. 51. ISSN 1471-2466. [consulta: 9 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/177028

Exportar metadades

JSON - METS

Compartir registre